Q-Med builds new offices and laboratory in Uppsala for SEK 130 million

Q-MED BUILDS NEW OFFICES AND LABORATORY IN UPPSALA FOR SEK 130 MILLION * Occupancy planned to start during the first half of 2002. * A total of 11,000 m2 to be built next to the existing facilities. * An all-in contract has been made with JM AB to carry out the work. JM have been commissioned to build Q-Med's new office and laboratory premises adjacent to the previous facilities in Librobäck, Uppsala. The contract amounts to SEK 130 million and in all it comprises 11,000 m2. While production is ongoing Q-Med will, in addition to its existing facilities, also rent offices in Nordviror's previous premises in Kungsängen near the River Fyris, which JM and Skanska have recently acquired with a view to developing a new district in Uppsala. Pending a detailed plan and planning permission, it is intended to rent out existing premises in Kungsängen, where Q-Med will thus become a large temporary tenant. Completion of Q-Med's new premises in Librobäck will take place over a period of time and they will be occupied in stages during 2002. "In order to secure our continued growth and thus the need for both production, laboratory and office premises, we are now making a considerable investment in the extension of our facilities in Uppsala. After the extension we will be dimensioned for a staffing of 300 persons in Uppsala," says P.O. Wallström, Q-Med's President and CEO. December 14, 2000 Uppsala, Sweden Q-Med AB (publ) Per Olof Wallström, President and CEO Queries should be addressed to Per Olof Wallström, President and CEO, on +46(0)18-474 90 00 or +46(0)70-974 90 70. Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. Q-Med's operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation. The products RESTYLANE, RESTYLANE Fine Lines and PERLANE are used for the filling out of lips and facial wrinkles and today account for the majority of sales. The development of MACROLANE for breast augmentation is ongoing. DUROLANE, Q-Med's product for the treatment of osteoarthritis in the knee-joint, is in the clinical documentation phase. DEFLUX is a product which has been approved in Europe for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children and stress urinary incontinence in women. Since July 2000 Q-Med has held a majority interest in the American biotechnology company Ixion Biotechnology, Inc., which carries out research within cell therapy for diabetes. Q-Med today has 195 employees, with 140 at the company's production facility and head office in Uppsala, 15 at Ixion and the remainder in wholly owned foreign subsidiaries. The Q-Med share has been listed on the O-list of the OM Stockholm Stock Exchange since December 1999. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Home page: www.q-med.com ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/12/14/20001214BIT00480/bit0001.doc http://www.bit.se/bitonline/2000/12/14/20001214BIT00480/bit0002.pdf